S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
BURLINGTON, Mass. - Bone Biologics Corporation (NASDAQ:BBLG), a developer of orthobiologic products currently trading at $0.81 with a market capitalization of $2.64 million, has declared a 1-for-6 reverse stock split, set to be effective at the beginning of trading on June 10, 2025. According to InvestingPro data, the stock has declined over 8% in the past week, reflecting recent market pressure. The decision, approved by stockholders at the annual meeting on May 30, 2025, aims to consolidate every six shares of issued and outstanding common stock into one share.
The reverse stock split was authorized within a range of 1-for-2.5 to 1-for-10, with the board of directors settling on the 1-for-6 ratio. Following the split, Bone Biologics will maintain its trading symbol BBLG on Nasdaq, and the common stock will be assigned a new CUSIP number, 098070600, though the par value per share will remain at $0.001. InvestingPro analysis suggests the stock is currently undervalued, with analysts setting a significantly higher target price of $16.50. Adjustments will also be made to the per-share exercise prices and the number of shares issuable under all outstanding warrants and equity awards to reflect the reverse stock split.
Stockholders’ percentage ownership in the company will stay unchanged, barring any fractional shares resulting from the reverse stock split, which will be rounded up to the nearest whole share. The total number of authorized shares of common stock will not be altered post-split.
Bone Biologics, focused on regenerative medicine for bone, is currently prioritizing the development of its bone graft substitute product for spinal fusion procedures. It also holds rights to applications in trauma and osteoporosis. While the company maintains strong liquidity with a current ratio of 12.59 and more cash than debt on its balance sheet, InvestingPro data indicates challenges ahead, with analysts forecasting continued losses for 2025. The company’s future plans and expectations, outlined in the press release, are forward-looking statements subject to risks and uncertainties, including market conditions and the inherent challenges faced by an undercapitalized developing company.
This report is based on a press release statement from Bone Biologics Corporation.
In other recent news, Bone Biologics Corp held its annual stockholders’ meeting, where several significant proposals were approved. Shareholders agreed to amend the company’s 2015 Equity Incentive Plan, increasing the number of shares reserved for issuance by 30 million. This amendment aims to provide more flexibility in compensating and incentivizing employees, directors, and consultants. Additionally, the appointment of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. A reverse stock split, ranging from 1-for-2.5 to 1-for-10, was also approved, pending further board approval. The meeting included the election of four director nominees and approval of the company’s executive compensation on an advisory basis. Bone Biologics Corp had earlier announced that its 2025 Annual Meeting of Stockholders was set for May 30, 2025, with updated deadlines for shareholder proposals and director nominations. These recent developments were communicated through press releases from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.